Investor Update, page-169

Anteo’s Chief Executive Officer, Christopher Parker, said: “GeneoDX have moved very rapidly to advance this distribution agreement, and the quality of the introductions to IVD and POC companies in China can only be described as first rate. Many are now actively assessing our new Anteo products and how these could be integrated with existing product manufacturing processes.

“Training, marketing activities and commercial negotiations are ongoing. With the CACLP exhibition next month, and through GeneoDX’s own activities, we are confident the pipeline of commercial agreements in China will grow rapidly. We look forward to updating shareholders on these developments and delivering tangible sales outcomes”.

That update is to be expected next week, from Monday onward.
CACLP until Sunday.


Initial feedback from ‘collaborator 1’ has been received well and has set the agreed program for the next phase of half-cell battery evaluation which is expected to be complete by early April.

Possibly a flurry of updates to be expected within the next 2 weeks.
How likely is it that management rushes back from China with possibly multiple tangible outcomes from the CACLP and announces a 500 mil shares issuance for 1.5 cent?

Broker applied simply the worst possible scenario for dilution to meet the costs for developing the products inhouse to meet responsibilities for activities shared by partners.
Those assumptions were statistically listed without considerations of possible share price increases from future ann and without any revenue generated from POC products in the near future.

It did scare the market, which needs to play catch up within the next 2 weeks, in my humble opinion.